ARTICLE | Finance
Brisk demand for follow-ons could augur IPO appetite: Public Equity Report
Four biotechs upsize follow-ons to raise $665M total, while NASDAQ queue grows
January 23, 2026 9:07 PM UTC
If robust appetite for follow-ons represents a sign that the IPO market is warming, this week’s filings and fundings add to the body of evidence that 2026 could fulfill the promise of a biotech rebound.
All four public biotechs raising nine-digit follow-ons upsized their offerings, while the NASDAQ queue grew in the wake of the Jan. 8 listing by Aktis Oncology Inc. (NASDAQ:AKTS) that raised $365 million...